Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.
Can Almirall turn dermatology momentum into a stronger long-term innovation engine?
Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.